A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients

PURPOSE: Simvastatin has demonstrated anti-tumor activity in preclinical studies via tumor cell senescence, apoptosis, and anti-angiogenesis. This phase II trial evaluated the efficacy and toxicity profile of conventional XELOX and bevacizumab chemotherapy plus simvastatin in metastatic colorectal c...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Youjin, Kim, Tae Won, Han, Sae Won, Ahn, Joong Bae, Kim, Seung Tae, Lee, Jeeyun, Park, Joon Oh, Park, Young Suk, Lim, Ho Yeong, Kang, Won Ki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639242/
https://www.ncbi.nlm.nih.gov/pubmed/30477287
http://dx.doi.org/10.4143/crt.2018.379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639242/
https://www.ncbi.nlm.nih.gov/pubmed/30477287
http://dx.doi.org/10.4143/crt.2018.379

Ejemplares similares